Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Onconetix, Inc. (Nasdaq: ONCO) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering a structured view of how this commercial-stage biotechnology company reports on its men’s health and oncology business. Onconetix’s filings span registration statements, current reports, and proxy materials, each providing different angles on its operations, capital structure, and governance.
Through registration statements on Form S‑1 and S‑1/A, Onconetix details equity financing arrangements such as PIPE transactions involving Series D and Series E convertible preferred stock and associated warrants, as well as an equity line of credit with Keystone Capital Partners. These documents describe the number of shares registered for resale, conversion and exercise prices, and the company’s status as a smaller reporting company and emerging growth company. They also explain the impact of the company’s 1‑for‑85 reverse stock split on share counts and per‑share data.
Current reports on Form 8‑K provide timely disclosure of material events, including PIPE financing closings, licensing agreements, promissory notes, Nasdaq listing notices, and strategic transactions. For example, 8‑K filings describe the terms of the Series D and Series E preferred stock and warrants, the licensing agreement between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and amendments and waivers associated with promissory notes tied to the ENTADFI asset acquisition.
The company’s definitive proxy statement on Schedule 14A outlines proposals for stockholder approval, such as director elections, ratification of the independent registered public accounting firm, and approvals required under Nasdaq rules for issuing common stock upon conversion of preferred stock and exercise of warrants. These materials also confirm the date and location of the annual meeting and summarize the board’s recommendations.
On Stock Titan, each new 10‑K, 10‑Q, 8‑K, S‑1, DEF 14A, or other filing is captured as it becomes available from EDGAR. AI-powered tools can be used to highlight key sections, such as risk factors, descriptions of Proclarix and ENTADFI, financing terms, and Nasdaq compliance disclosures. Users interested in insider activity can also review Form 4 filings, when available, to see reported transactions by directors and officers.
By using this page, investors and researchers can quickly locate Onconetix’s quarterly and annual reports, capital raising disclosures, and governance documents, and rely on AI summaries to interpret complex sections without reading every page of the underlying filings.
Onconetix, Inc. summarizes Realbotix's update that Realbotix expects delivery of 19 previously ordered humanoid robots and associated AI implementations across March, April, and May 2026. Onconetix previously entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all‑stock transaction. The combined company is expected to trade on Nasdaq following closing, which Onconetix anticipates in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. Onconetix states it will file a Registration Statement on Form S-4 to register shares to be issued in the transaction.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026 and Sammy Dorf as a director and Audit Committee member effective March 19, 2026.
The company states these leadership changes come as it advances a definitive agreement to acquire Realbotix LLC and intends to file a Registration Statement on Form S-4 to register Onconetix common stock to be issued in the transaction.
Onconetix, Inc. is asking stockholders at an April 30, 2026 special meeting to approve authority for one or more reverse stock splits of its common stock at ratios between 1-for-2 and 1-for-10, with all such splits together capped at 1-for-100 and usable for one year.
The aim is to maintain compliance with Nasdaq’s $1.00 minimum bid requirement after prior notices under the Bid Price Rule and Low Priced Stocks Rule, and to support liquidity and future capital-raising. A second proposal would allow adjournment of the meeting to solicit additional proxies. There were 692,927 common shares outstanding as of March 13, 2026.
Onconetix, Inc. filed an initial insider ownership report for Chief Executive Officer David Allan White on Form 3. This filing establishes his status as an executive officer and subject to insider reporting rules, but it does not disclose any specific stock transactions or option exercises.
Onconetix, Inc. director Sammy Dorf filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his equity position under Section 16 reporting, but it does not list any transactions, purchases, or sales of Onconetix stock.
Onconetix, Inc. has implemented a 1-for-5 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 25, 2026. The company’s shares continue to trade on The Nasdaq Capital Market under the symbol ONCO with a new CUSIP number 68237Q 302.
Every five issued and outstanding shares of common stock were automatically converted into one share, with no change to the par value and no reduction in the number of authorized shares. The reverse split reduced the number of issued and outstanding shares from 3,464,686 to 692,927 and is intended to help the company maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.
No fractional shares were issued; instead, stockholders entitled to a fractional share receive cash based on the closing sale price on March 24, 2026, adjusted for the split. Proportional adjustments were also made to equity awards, convertible preferred stock, and warrants.
Onconetix highlights Realbotix participation in Ericsson’s live pre-standard 6G over-the-air trial and reiterates its pending acquisition of Realbotix LLC. A Realbotix humanoid robot served as a live connected endpoint transmitting video and interacting in real time over Ericsson’s test network. Onconetix entered a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction; closing is anticipated in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
Onconetix, Inc. filed an amended report to add the employment agreement for its new Chief Executive Officer, David White, as an exhibit. The amendment does not change any prior disclosures.
The Board appointed Mr. White as CEO effective March 18, 2026, under an employment agreement providing a monthly base salary of $21,700 and customary non-compete, confidentiality and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement over operations or policies. The Board appointed Sammy Dorf as a new director and member of the Audit Committee, adding capital-markets and governance experience.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026, formalizing leadership after an interim period. White brings more than 30 years of executive and board experience across transportation, healthcare, and manufacturing, including prior CEO, CFO, and COO roles and multiple public company directorships.
Under his employment agreement, White will receive a monthly base salary of $21,700 and is subject to non-compete, confidentiality, and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for Interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley, effective March 18, 2026.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement with management or the Board. The Board appointed entrepreneur and investor Sammy Dorf as a new director and Audit Committee member, adding capital markets and governance experience. Both White and Dorf are described as independent, with no family relationships or related-party transactions requiring disclosure.
Onconetix, Inc. is seeking stockholder approval at a Special Meeting on April 30, 2026 to authorize the Board to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-10 (aggregate up to 1-for-100) and to approve an adjournment power.
The Board unanimously recommends a FOR vote. The Record Date for voting is March 13, 2026, and 3,473,352 shares of Common Stock were outstanding as of that date. The proposal would let the Board decide timing and the final ratio, and any Reverse Stock Split would become effective upon filing an amendment with Delaware.